Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions

被引：14

作者：

An, Yan-Fei ^{[1
,2
,3
,4
]}

Pu, Ning ^{[1
,5
,6
]}

Jia, Jin-Bin ^{[3
,4
]}

Wang, Wen-Quan ^{[1
,5
,6
]}

Liu, Liang ^{[1
,5
,6
]}

机构：

[1] Fudan Univ, Dept Pancreat Surg, Zhongshan Hosp, 56 Xinjian South Rd, Shanghai 200032, Peoples R China

[2] Chang Zhi Med Coll, Dept Basic Med, Changzhi 046000, Peoples R China

[3] Shan Xi Med Univ, Dept Basic Med, 56 Xinjian South Rd, Taiyuan 030000, Peoples R China

[4] Shan Xi Med Univ, Inst Liver Dis, 56 Xinjian South Rd, Taiyuan 030000, Peoples R China

[5] Fudan Univ, Zhongshan Hosp, Canc Ctr, Shanghai 200032, Peoples R China

[6] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai 200032, Peoples R China

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2023年 / 1878卷 / 05期

基金：

中国博士后科学基金; 中国国家自然科学基金;

关键词：

Pancreatic cancer; Angiogenesis; Anti-angiogenic therapy; Vascular remodeling; TME reprogramming; ENDOTHELIAL GROWTH-FACTOR; GEMCITABINE PLUS PLACEBO; RANDOMIZED PHASE-II; ANTI-VEGF TREATMENT; VESSEL CO-OPTION; DOUBLE-BLIND; DUCTAL ADENOCARCINOMA; VASCULOGENIC MIMICRY; ENHANCES IMMUNOTHERAPY; MEDIATES RESISTANCE;

D O I：

10.1016/j.bbcan.2023.188958

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pancreatic cancer (PC) is one of the most lethal malignancies, which is generally resistant to various treatments. Tumor angiogenesis is deemed to be a pivotal rate-determining step for tumor growth and metastasis. Therefore, anti-angiogenetic therapy is a rational strategy to treat various cancers. However, numerous clinical trials on anti-angiogenetic therapies for PC are overwhelmingly disappointing. The unique characteristics of tumor blood vessels in PC, which are desperately lacking and highly compressed by the dense desmoplastic stroma, are reconsidered to explore some optimized strategies. In this review, we mainly focus on its specific characteristics of tumor blood vessels, discuss the current dilemmas of anti-angiogenic therapy in PC and their underlying mechanisms. Furthermore, we point out the future directions, including remodeling the abnormal vasculature or even reshaping the whole tumor microenvironment in which they are embedded to improve tumor microcir-culation, and then create therapeutic vulnerabilities to the current available therapeutic strategies.

引用

页数：15

共 147 条

[1] Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma [J].

Aguilera, Kristina Y. ;

Rivera, Lee B. ;

Hur, Hoon ;

Carbon, Juliet G. ;

Toombs, Jason E. ;

Goldstein, Courtney D. ;

Dellinger, Michael T. ;

Castrillon, Diego H. ;

Brekken, Rolf A. .

CANCER RESEARCH, 2014, 74 (04) :1032-1044

[2] Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition [J].

Allen, Elizabeth ;

Walters, Ian B. ;

Hanahan, Douglas .

CLINICAL CANCER RESEARCH, 2011, 17 (16) :5299-5310

[3] Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer [J].

Bausch, Dirk ;

Fritz, Stefan ;

Bolm, Louisa ;

Wellner, Ulrich F. ;

Fernandez-del-Castillo, Carlos ;

Warshaw, Andrew L. ;

Thayer, Sarah P. ;

Liss, Andrew S. .

ANGIOGENESIS, 2020, 23 (03) :479-492

[4] Notch signaling regulates vasculogenic mimicry and promotes cell morphogenesis and the epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma [J].

Benjakul, Nontawat ;

Prakobphol, Nattapa ;

Tangshewinsirikul, Chayada ;

Dulyaphat, Wirada ;

Svasti, Jisnuson ;

Charngkaew, Komgrid ;

Kangsamaksin, Thaned .

PLOS ONE, 2022, 17 (12)

[5] A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer [J].

Bergmann, L. ;

Maute, L. ;

Heil, G. ;

Ruessel, J. ;

Weidmann, E. ;

Koeberle, D. ;

Fuxius, S. ;

Weigang-Koehler, K. ;

Aulitzky, W. E. ;

Woermann, B. ;

Hartung, G. ;

Moritz, B. ;

Edler, L. ;

Burkholder, I. ;

Scheulen, M. E. ;

Richly, H. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (01) :27-36

[6] Cytokines in clinical cancer immunotherapy [J].

Berraondo, Pedro ;

Sanmamed, Miguel F. ;

Ochoa, Maria C. ;

Etxeberria, Inaki ;

Aznar, Maria A. ;

Luis Perez-Gracia, Jose ;

Rodriguez-Ruiz, Maria E. ;

Ponz-Sarvise, Mariano ;

Castanon, Eduardo ;

Melero, Ignacio .

BRITISH JOURNAL OF CANCER, 2019, 120 (01) :6-15

[7] Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+Cancer Cells in Locally Advanced Pancreatic Cancer [J].

Boucher, Yves ;

Posada, Jessica M. ;

Subudhi, Sonu ;

Kumar, Ashwin S. ;

Rosario, Spencer R. ;

Gu, Liqun ;

Kumra, Heena ;

Mino-Kenudson, Mari ;

Talele, Nilesh P. ;

Duda, Dan G. ;

Fukumura, Dai ;

Wo, Jennifer Y. ;

Clark, Jeffrey W. ;

Ryan, David P. ;

Fernandez-Del Castillo, Carlos ;

Hong, Theodore S. ;

Pittet, Mikael J. ;

Jain, Rakesh K. .

CLINICAL CANCER RESEARCH, 2023, 29 (08) :1605-1619

[8] Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) [J].

Bozzarelli, Silvia ;

Rimassa, Lorenza ;

Giordano, Laura ;

Sala, Simona ;

Tronconi, Maria Chiara ;

Pressiani, Tiziana ;

Smiroldo, Valeria ;

Prete, Maria G. ;

Spaggiari, Paola ;

Personeni, Nicola ;

Santoro, Armando .

FUTURE ONCOLOGY, 2019, 15 (35) :4009-4017

[9] Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models [J].

Bridgeman, Victoria L. ;

Vermeulen, Peter B. ;

Foo, Shane ;

Bilecz, Agnes ;

Daley, Frances ;

Kostaras, Eleftherios ;

Nathan, Mark R. ;

Wan, Elaine ;

Frentzas, Sophia ;

Schweiger, Thomas ;

Hegedus, Balazs ;

Hoetzenecker, Konrad ;

Renyi-Vamos, Ferenc ;

Kuczynski, Elizabeth A. ;

Vasudev, Naveen S. ;

Larkin, James ;

Gore, Martin ;

Dvorak, Harold F. ;

Paku, Sandor ;

Kerbel, Robert S. ;

Dome, Balazs ;

Reynolds, Andrew R. .

JOURNAL OF PATHOLOGY, 2017, 241 (03) :362-374

[10] Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy [J].

Cantelmo, Anna Rita ;

Conradi, Lena-Christin ;

Brajic, Aleksandra ;

Goveia, Jermaine ;

Kalucka, Joanna ;

Pircher, Andreas ;

Chaturvedi, Pallavi ;

Hol, Johanna ;

Thienpont, Bernard ;

Teuwen, Laure-Anne ;

Schoors, Sandra ;

Boeckx, Bram ;

Vriens, Joris ;

Kuchnio, Anna ;

Veys, Koen ;

Cruys, Bert ;

Finotto, Lise ;

Treps, Lucas ;

Stav-Noraas, Tor Espen ;

Bifari, Francesco ;

Stapor, Peter ;

Decimo, Ilaria ;

Kampen, Kim ;

De Bock, Katrien ;

Haraldsen, Guttorm ;

Schoonjans, Luc ;

Rabelink, Ton ;

Eelen, Guy ;

Ghesquiere, Bart ;

Rehman, Jalees ;

Lambrechts, Diether ;

Malik, Asrar B. ;

Dewerchin, Mieke ;

Carmeliet, Peter .

CANCER CELL, 2016, 30 (06) :968-985

← 1 2 3 4 5 6 7 8 9 10 →